Tag:
Accelrys
Latest Headlines
Latest Headlines
Accelrys snaps up discovery software from Scynexis
Accelrys ($ACCL) has beefed up its software offerings for virtual biotech teams. The San Diego-based company has acquired technology and personnel from drug developer Scynexis related to an SaaS product called Hit Explorer Operating System.
BT touts cloud for biopharma R&D collaboration
BT Global has run to the market with a cloud-based service that allows biopharma companies to conduct global collaborations.
Sequencing DNA with a thumb drive faces skepticism
Some competitors are questioning whether Oxford Nanopore's device will live up to its billing.
Accelrys stays on growth track in Q4
Accelrys ($ACCL) has bested analysts' estimates on the San Diego company's revenue for the fourth quarter. The provider of lab software for biopharma groups recorded $39.8 million in...
Accelrys CEO hints at more buyouts after VelQuest acquisition
As reported here Tuesday, Accelrys ( $ACCL ), one of the world's biggest providers of R&D software, has expanded into the quality control arena with its $35 million buyout of VelQuest. And the
Accelrys bulks up software offerings in $35M VelQuest buyout
With its R&D software facing lots of competition, Accelrys ( $ACCL ) made a move announced today to expand its menu of applications into the drug-manufacturing arena. The San Diego-based company is
Accelrys stock price dips on 3Q earnings
R&D software maker Accelrys ( $ACCL ) has taken a bit of hit today after reporting financial results. The San Diego-based firm has sought growth through acquisitions over the past year and a half,...
Accelrys brings drug discovery projects to the cloud
Accelrys ($ACCL), the San Diego-based scientific software firm, has unveiled its next-gen informatics system called the Cheminformatics Suite. The suite has new tools, including a web-based system
Accelrys' Q2 revenue up 86% after mergers
Accelrys, one of the world's largest providers of life sciences research software, saw its revenue for the second quarter spike with additional income streams from its acquisitions of Symyx and
Accelrys integrates MIT tech into updated lab software
With the new release of its key life sciences modeling and simulation software, Accelrys ( $ACCL ) has added algorithms licensed from MIT that were developed to aid in the design of biologic drugs such
